Search results

The problem with that is that this test is scientifically validated and FDA approved (which is a specified independent non-profit authority). It's scientifically validated that it measures antibodies, the problem is just that this measurement is essentially meaningless. There's sort of two...

I most definitely share this concern. Especially since things don’t seem to be improving. But I also don’t know how this could be easily addressed. Supposedly the founders of Celltrend believed that GPCR-aabs played a role in ME/CFS but couldn’t measure them and as such founded a company that...

I would say if the test, tests spitting on copper sulphate and it turns blue and all the test claims to do is exactly that it wouldn't be a fake test, just an inherently useless one and I certainly agree, that this test as well as the Celltrend test would show nothing but their own results. As...

I don't disagree that the test is meaningless (at least based on all currently available evidence). But philosophically that is different to something being a "fake test", at least the way I interpret it. A "fake test" in my eyes would be something that is somehow inaccurate or gives results...

I agree that the test is currently meaningless for ME/CFS, but that doesn't mean that the test is inaccurate or a "fake test". On the contrary I would say having a test can only be more valuable than not having a test as long as the test is accurate. ELISA is generally considered to be highly...

That doesn't mean the tests are "fake" as I tried to clarify in my post. They don't yield inaccurate results, they appear to be accurate for what they are measuring (antibodies against GPCR in blood via ELISA). The tests simply imply that based on current research the ELISA tests are meaningless...

Why should they clamp down on something like Celltrend? Is there any reason to believe that their tests are inaccurate? From what I can tell their tests are accurate, their results currently just don't have any meaning for LC and/or ME/CFS. Furthermore their tests are supposedly valuable for...

What about non-mild long-term health outcomes that don't directly correlate with the severity of an acute infection, since the rest has been known for years?

Seems like an easy enough thing to do. I'm guessing their methodology isn't the most rigorous though, at least there are no controls which many other papers have had and other papers seem a bit more rigorous to me as layman. "The median duration since the last infection was reported as 17...

Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination Abstract Background and study aims Gut infection is common during acute COVID-19, and persistent SARS-CoV-2 gut infection has been reported months after the initial...

Even after decades of research there no such thing as a blood marker for MS exists (and those things that some believe to play an important role such as sNfL and sGFAP are completely different to his experiments from what I can tell), so what they are detecting in their experiments can a priori...

Thanks for sharing. Whilst I share your doubts, what he says on Twitter sounds like a somewhat reasonable approach. I even have some small doubts about the LC cohort (possible BMI problems discussed here), but it will also be nice to see further results for a cohort that has already been studied...

I don't think Davis ever made such a claim. I might be wrong this time, but previously when patients were making the claim that half of ME/CFS patients have MS, the basis for that was that Davis had said that they are finding antibodies to MBP in half of their ME/CFS samples (see also the...

Now published as the Letter Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2 in Nature Immonology. Haven't seen if there's new data compared to the preprints, but the reviewers wanted quite a few changes so perhaps there's...

I contacted one of the authors regarding their interesting findings with questions I had, many of which were also asked in this forum. As such I thought it might be interesting if I provided some of the answers, to be precise my own interpretation of the answers, that I received. The stool...

Can’t say much about the methodology used other than that they used YLD (“years lived with disability”) rather than DALYs which others commonly use. I’m not sure how accurate the official source for NIH funding is https://report.nih.gov/funding/categorical-spending#/. It doesn’t include the NIH...

Long COVID Disability Burden in US Adults: YLDs and NIH Funding Relative to Other Conditions Abstract Background- Long COVID (LC) is novel, debilitating and likely chronic. Yet, scant data exist about its disability burden to guide scientific research and public health planning. We estimated...

How does one obtain a Chronic Lyme (I'm assuming that this is equivalent to Post-Treatment Lyme Disease Syndrome) cohort? Isn't the diagnosis typically made on the basis of tests that are highly unreliable? Are there serious researchers in the field that have also established rigorous cohorts...

Alan Carson is one of the authors.

First study seems to be about 6 weeks after the acute infection, third study also seems to be suffering from cohort problems. The second study might also have some problems w.r.t. to that (older population, majority males, smokers, hospitalisation, etc) but looks interesting and rigorous enough...